These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 23892527)

  • 41. Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: a case-control study.
    Chau GY; Lui WY; Tsay SH; Chao Y; King KL; Wu CW
    Ann Surg Oncol; 2006 Oct; 13(10):1329-37. PubMed ID: 16897271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
    Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
    Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review.
    Cai XR; Li X; Lin JX; Wang TT; Dong M; Chen ZH; Jia CC; Hong YF; Lin Q; Wu XY
    Oncotarget; 2017 May; 8(19):31318-31328. PubMed ID: 28412743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant dendritic cells vaccine combined with cytokine-induced-killer cell therapy after renal cell carcinoma surgery.
    Zheng K; Tan JM; Wu WZ; Qiu YM; Zhang H; Xu TZ; Sun XH; Zhuo WL; Wang D; Zhang JP
    J BUON; 2015; 20(2):505-13. PubMed ID: 26011343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
    Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significance of reduction surgery in multidisciplinary treatment of advanced hepatocellular carcinoma with multiple intrahepatic lesions.
    Wakabayashi H; Ushiyama T; Ishimura K; Izuishi K; Karasawa Y; Masaki T; Watanabe S; Kuriyama S; Maeta H
    J Surg Oncol; 2003 Feb; 82(2):98-103. PubMed ID: 12561065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytokine-induced killer cell infusion combined with conventional treatments produced better prognosis for hepatocellular carcinoma patients with barcelona clinic liver cancer B or earlier stage: A systematic review and meta-analysis.
    Li YC; Zhao L; Wu JP; Qu CX; Song QK; Wang RB
    Cytotherapy; 2016 Dec; 18(12):1525-1531. PubMed ID: 27746013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial.
    Olioso P; Giancola R; Di Riti M; Contento A; Accorsi P; Iacone A
    Hematol Oncol; 2009 Sep; 27(3):130-9. PubMed ID: 19294626
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy.
    Ueno M; Uchiyama K; Ozawa S; Hayami S; Shigekawa Y; Tani M; Yamaue H
    Ann Surg Oncol; 2011 Dec; 18(13):3624-31. PubMed ID: 21614626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The value of portal vein chemotherapy after radical resection in delaying intrahepatic recurrence of stage II primary hepatocellular carcinoma].
    Zhang GQ; Ge L; Ding W; Li HJ
    Ai Zheng; 2008 Dec; 27(12):1297-301. PubMed ID: 19079997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemotherapy in combination with cytokine-induced killer cell transfusion: An effective therapeutic option for patients with extensive stage small cell lung cancer.
    Huang J; Kan Q; Lan ; Zhao X; Zhang Z; Yang S; Li H; Wang L; Xu L; Cheng Z; Zhang Y
    Int Immunopharmacol; 2017 May; 46():170-177. PubMed ID: 28292730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of the Clinical Efficacy of Dendritic Cell -cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer.
    Xu H; Qin W; Feng H; Song D; Yang X; Zhang J
    Immunol Invest; 2021 Aug; 50(6):622-633. PubMed ID: 32718264
    [No Abstract]   [Full Text] [Related]  

  • 53. MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.
    Wang Z; Liu Y; Zhang Y; Shang Y; Gao Q
    Oncotarget; 2016 Jan; 7(4):4760-9. PubMed ID: 26716894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multimodality management of hepatocellular carcinoma larger than 10 cm.
    Mok KT; Wang BW; Lo GH; Liang HL; Liu SI; Chou NH; Tsai CC; Chen IS; Yeh MH; Chen YC
    J Am Coll Surg; 2003 Nov; 197(5):730-8. PubMed ID: 14585406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Impact of surgical operation-related factors on long-term survival of patients with hepatocellular carcinoma after hepatectomy].
    Lü WP; Dong JH; Zhang WZ; Huang XQ; Wang SG; Bie P
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):386-92. PubMed ID: 18795607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Efficacy and Safety of Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cell Therapy in Combination with TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma: a Meta-Analysis.
    Su Y; Yang Y; Ma Y; Zhang Y; Rao W; Yang G; Kou C
    Clin Lab; 2016; 62(4):599-608. PubMed ID: 27215078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Co-culture of dendritic cells and cytokine-induced killer cells effectively suppresses liver cancer stem cell growth by inhibiting pathways in the immune system.
    Yang T; Zhang W; Wang L; Xiao C; Wang L; Gong Y; Huang D; Guo B; Li Q; Xiang Y; Nan Y
    BMC Cancer; 2018 Oct; 18(1):984. PubMed ID: 30326865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.
    Lin M; Liang S; Jiang F; Xu J; Zhu W; Qian W; Hu Y; Zhou Z; Chen J; Niu L; Xu K; Lv Y
    Immunol Lett; 2017 Mar; 183():37-43. PubMed ID: 28143792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection.
    Pandey D; Lee KH; Wai CT; Wagholikar G; Tan KC
    Ann Surg Oncol; 2007 Oct; 14(10):2817-23. PubMed ID: 17690940
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prognostic factors influencing postoperative survival in patients with Wu FS; Zhao WH; Liang TB; Ren GP; Ma ZM; Teng LS
    Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):579-83. PubMed ID: 15938929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.